Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
94616 trials found · Page 136 of 4731
-
New drug duo aims to wipe out hidden leukemia cells
Disease control Not yet recruitingThis phase II trial tests how well nemtabrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is pre…
Phase: PHASE2 • Sponsor: Jennifer Woyach • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Engineered immune cells take on tough liver cancer in early trial
Disease control TerminatedThis phase I trial studies the side effects and best dose of RPCAR01 chimeric antigen receptor (CAR) T cells and to see how well it works in treating patients with GPC3 expressing hepatocellular carcinoma (HCC) that may have spread from where it first started to nearby tissue, ly…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Computer guidance may sharpen liver cancer treatment
Disease control Recruiting nowThe goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults. The employed software calculates and displays a simulation of the ablation such that the physician can visualize what p…
Phase: NA • Sponsor: NE Scientific INC • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New triple therapy targets rare neuroendocrine cancers in first-line trial
Disease control Not yet recruitingTo explore the Objective Response Rate (ORR) of Benmelstobart combined with Anlotinib and chemotherapy as first-line treatment for large-cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinoma (EP-NEC)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Nasal spray during labor may ward off postpartum depression
Prevention Not yet recruitingBrief Title: Intranasal Dexmedetomidine for Postpartum Depression Prevention: A Randomized Trial This study aims to evaluate the effect of intranasal dexmedetomidine (Dex) administered before combined spinal-epidural labor analgesia on the incidence of postpartum depression (PPD)…
Phase: NA • Sponsor: Chengdu Jinjiang Maternity and Child Health Hospital • Aim: Prevention
Last updated May 13, 2026 16:03 UTC
-
Smart scans guide tailored chemo for HER2+ breast cancer
Disease control Not yet recruitingThis study evaluates HER2-PET/CT-guided dynamic optimization of neoadjuvant therapy in patients with early-stage HER2-positive breast cancer. Based on metabolic response after two cycles, patients receive either intenstified treatment (Arm A) or de-escalation treatment (Arm B), a…
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New urine test could spare men unnecessary prostate biopsies
Diagnosis Not yet recruitingThis clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likeliho…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Diagnosis
Last updated May 07, 2026 18:41 UTC
-
AI and CT scans join forces to catch lung cancer sooner in latin america
Diagnosis Not yet recruitingProspective study to assess lung cancer screening with low dose CT scan (LDCT) in Latin America (LATAM) and prospectively evaluate chest-XRay analyzed with artificial intelligence (AI) using qXRin (QURE ai) at the initial visit correlating with the findins of the initial LDCT in …
Sponsor: Latin American Consortium for the Lung Cancer Research • Aim: Diagnosis
Last updated May 14, 2026 12:05 UTC
-
New immune booster aims to stop childhood cancer return after transplant
Disease control Not yet recruitingA first-in-class adoptive immunotherapy we called ThINKK, for Therapeutic Inducers of Natural Killer (NK) cell Killing, have been designed for use after hematopoietic stem cell transplantation (HSCT), where the proper stimulation of graft-derived NK cells has been shown to preven…
Phase: PHASE1 • Sponsor: Michel Duval • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Bone-Stretching trick may save feet from diabetes wounds
Disease control Not yet recruitingThis study is a single-center, prospective, randomized controlled trial aimed at evaluating whether periosteal distraction combined with autologous split-thickness skin grafting can significantly improve graft survival rate at postoperative day 14 compared with skin grafting alon…
Phase: NA • Sponsor: Hu Zhicheng • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New scan spots hidden heart clots in rare disease
Diagnosis Recruiting nowThe primary goal of this pilot study is to determine whether \[64Cu\]FBP8, a novel fibrin-binding positron emission tomography (PET) probe, can identify intracardiac thrombi when paired with simultaneous hybrid cardiac PET/MRI in twenty (20) individuals with transthyretin or ligh…
Phase: PHASE3 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated May 04, 2026 16:22 UTC
-
Simple nose procedure may prevent severe radiation damage in recurrent cancer patients
Prevention Not yet recruitingThis study aims to evaluate the effectiveness and safety of endoscopic nasopharyngeal pseudomembrane removal in reducing radiation-induced nasopharyngeal necrosis in patients with recurrent nasopharyngeal carcinoma who have received re-irradiation. This is a prospective, single-a…
Phase: NA • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Prevention
Last updated May 12, 2026 13:41 UTC
-
New hope for hard-to-treat lung cancer: targeted therapy MK-1084 enters trial
Disease control Recruiting nowResearchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * Ab…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New Triple-Drug attack shows promise against tough blood cancer
Disease control Not yet recruitingThis is a Phase I/II, single-arm, open-label clinical trial evaluating the safety and preliminary efficacy of a novel induction regimen combining Venetoclax, Azacitidine, and Liposomal Mitoxantrone (VAM) in adult patients with newly diagnosed Acute Myeloid Leukemia (AML) who are …
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Could a lower dose of Alzheimer's drug be just as effective?
Disease control Not yet recruitingThis study will analyze the clinical indicators, imaging data, and serum biomarkers of Alzheimer's disease (AD) patients receiving different doses of the medication before and after treatment. It aims to clarify whether the therapeutic efficacy in the low-dose group is equivalent…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Breathing gas during surgery may shield kidneys from damage
Prevention Not yet recruitingThe goal of this clinical trial is to learn if giving inhaled nitric oxide during heart surgery can prevent acute kidney injury (AKI) in patients who are at high risk of developing this complication. AKI is a serious problem after heart surgery and can lead to longer hospital sta…
Phase: NA • Sponsor: Shanghai Zhongshan Hospital • Aim: Prevention
Last updated May 04, 2026 16:24 UTC
-
New combo therapy aims to stop liver cancer from coming back after surgery
Disease control Not yet recruitingThis study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with high-risk features. (1) Evaluate for some high-risk patient…
Phase: PHASE1, PHASE2 • Sponsor: BinYong Liang • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New theranostic approach targets brain metastases in solid tumors
Disease control Not yet recruitingThis trial will evaluate treatment for patients with solid tumors with active brain metastases. Patients will be treated with a theranostic or diagnostic agent. Theranostic agents are targeted radioactive drugs used to identify (diagnose) and to deliver therapy. The main purpose …
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New drug RC288 targets Hard-to-Treat tumors in early trial
Disease control Not yet recruitingThe primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;
Phase: PHASE1, PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New eye drops could heal stubborn corneal wounds in weeks
Disease control Not yet recruitingThis is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants with PCED. The primary objective is the evaluation of…
Phase: PHASE3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated May 14, 2026 12:02 UTC